To analyze the clinical implications of DLX5 methylation, we divided the MDS and AML patients into two groups (DLX5 hypermethylation and DLX5 nonhypermethylation) according to the set cutoff value, respectively. This evidence concerns the gene DLX5 and myelodysplastic syndrome.